TLP
XFOR icon

Tri Locum Partners’s X4 Pharmaceuticals XFOR Stock Holding History

Tri Locum Partners’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-208,250
Closed -$6.81M – 60
2023
Q3 		$6.81M Buy
208,250
+71,585
+52% +$3.12M 2.18% 16
2023
Q2 		$7.95M Buy
136,665
+7,382
+6% +$379K 2.96% 13
2023
Q1 		$3.37M Buy
129,283
+5,732
+5% +$168K 1.03% 28
2022
Q4 		$3.68M Buy
123,551
+40,084
+48% +$1.9M 1.49% 24
2022
Q3 		$4.28M Buy
83,467
+25,524
+44% +$882K 1.18% 29
2022
Q2 		$1.68M Buy
57,943
+690
+1% +$26.2K 0.69% 29
2022
Q1 		$3.01M Buy
57,253
+4,621
+9% +$265K 1.17% 27
2021
Q4 		$3.62M Buy
+52,632
New +$6.66M 1.42% 19

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Tri Locum Partners's XFOR Position: Q4 2023 in Review

Tri Locum Partners sold out of X4 Pharmaceuticals (XFOR) in Q4 2023, closing a stake of 208,250 shares — an estimated $6.81M sold.

Tri Locum Partners first reported a position in XFOR in Q4 2021 and held it in 8 quarters. The position peaked at $7.95M in Q2 2023. 93 funds tracked by Wall St. Rank hold XFOR as of Q4 2023.

  • Tri Locum Partners reported no remaining X4 Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Tri Locum Partners sold 208,250 X4 Pharmaceuticals shares in Q4 2023, an estimated $6.81M.
  • Tri Locum Partners first reported a position in X4 Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Tri Locum Partners's X4 Pharmaceuticals position peaked at $7.95M in Q2 2023.
  • 93 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2023.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.